Key Takeaways

  • The company recorded a Q4 net loss of €305 million, reversing from a €259.5 million profit in the prior-year quarter
  • Management’s full-year 2026 revenue projection of €2–2.3 billion fell significantly short of analyst estimates at €2.75 billion
  • CEO Ugur Sahin and CMO Ozlem Tureci plan to depart by the end of the year to establish a new biotechnology firm
  • The company will transfer mRNA technologies to the founders’ new enterprise, receiving a minority ownership position plus royalty arrangements
  • Comirnaty vaccine sales are projected to continue declining across U.S. and European territories throughout 2026

BioNTech faced severe market reaction Tuesday following three simultaneous setbacks — quarterly losses, underwhelming projections, and founder exits. Shares plummeted 17% during premarket hours, marking the steepest single-session decline since December 2021.

The Mainz-based company disclosed a Q4 net loss totaling €305 million. This represents a sharp reversal from the €259.5 million profit recorded during the corresponding quarter twelve months prior. Quarterly revenue reached €907.4 million, declining from €1.19 billion.


BNTX Stock Card
BioNTech SE, BNTX

Per-share results showed BioNTech lost €1.25 during Q4. Analyst consensus had projected a smaller loss of €0.45, making the variance substantial.

The full-year forecast created greater concern among investors. The company established 2026 revenue guidance ranging from €2 billion to €2.3 billion. Analyst expectations had reached €2.75 billion — creating an approximate €450 million gap at the median.

Comirnaty vaccine sales represent the primary factor behind the revenue shortfall. Company leadership indicated they anticipate reduced Comirnaty performance throughout 2026 as demand continues weakening in both American and European territories.

Revenue from the Bristol Myers Squibb cancer immunotherapy partnership is projected to remain “broadly in line with 2025,” providing minimal support against declining Covid vaccine sales.

Founding Leadership Plans Departure

The leadership announcement added to investor concerns. CEO Ugur Sahin alongside Chief Medical Officer Ozlem Tureci — the married couple who established BioNTech in 2008 — revealed plans to exit the organization by December 2026 to create a new mRNA-focused biotechnology enterprise.

BioNTech’s supervisory board has initiated the succession process for both positions.

Management stated the company will transfer “related rights and mRNA technologies” to the founders’ new startup, receiving a minority equity position, milestone-based payments, and revenue royalties. Both organizations will maintain independent resources and funding structures.

Sahin and Tureci elevated BioNTech to global prominence throughout the Covid-19 pandemic, when their mRNA research enabled the development of the Comirnaty vaccine in partnership with Pfizer.

Regulatory Environment Shifts for mRNA Technology

The stock has encountered additional challenges from evolving regulatory dynamics in the United States. mRNA technology has experienced heightened examination following Robert F. Kennedy Jr.’s appointment as Secretary of Health and Human Services. The present administration has demonstrated skepticism toward mRNA vaccination platforms.

Prior to Tuesday’s decline, BNTX had posted gains of 7.3% in 2026. Pfizer, its Comirnaty development partner, had advanced 7.7% during the identical timeframe.

For comparison, Moderna had climbed 89% while Novavax rose 57% entering Tuesday — both significantly outperforming their larger competitors.

BioNTech’s adjusted R&D expenditure forecast for 2026 spans €2.2 billion to €2.5 billion, demonstrating continued commitment to its oncology development programs.

Management indicated plans to conduct 15 late-stage oncology clinical studies by year-end, targeting transformation into a diversified product company by 2030.

BioNTech’s American depository receipts traded at $84.59 during Tuesday’s premarket session, reflecting the 17% decline.